Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397951 · ClinicalTrials.gov registry record · NA
The Validation Study of Bioelectronics
A NA study of Healthy and Health Behavior, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05397951: Recruiting NA study of Healthy and Health Behavior, sponsored by University of North Carolina, Chapel Hill.
NCT05397951 is a NA study of Healthy and Health Behavior that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 22 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05397951, a NA study of Healthy and Health Behavior, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the safe wearability and basic functions of the multi-modality sensors fabricated in the PI lab.
Primary Outcome
A questionnaire about the comfort of the wearable sensors will be measured using the Likert scale, which ranges from 1 to 5 and is used to measure attitudes and perception changes about the our sensor. The minimum value 1 represents "strongly disagree" and the maximum value 5 represents "strongly agree", thus higher scores represent a better outcome.
Conditions Studied
Interventions
- DEVICE Multi-modality Noninvasive Biosensor
- DEVICE Oximeter
- DEVICE Portable Blood Pressure Monitor
- DEVICE Vicorder Pulse Wave Velocity Monitor
Study Locations (1)
North Carolina
- Kenan Laboratories at the University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-01-09 |
| Est. Completion | 2025-11 |
| Phase | NA |
What NCT05397951 shows while recruiting
NCT05397951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Multi-modality Noninvasive Biosensor is the first listed.
NCT05397951 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05397951 about?
NCT05397951 is a clinical study titled "The Validation Study of Bioelectronics". The purpose of this study is to investigate the safe wearability and basic functions of the multi-modality sensors fabricated in the PI lab.
What is the current status of trial NCT05397951?
This trial is currently recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2024-01-09. Estimated completion is 2025-11.
What conditions does trial NCT05397951 study?
This clinical trial studies the following conditions: Healthy, Health Behavior.
What interventions are being tested in trial NCT05397951?
The interventions under investigation include: Multi-modality Noninvasive Biosensor (DEVICE), Oximeter (DEVICE), Portable Blood Pressure Monitor (DEVICE), Vicorder Pulse Wave Velocity Monitor (DEVICE).
Who is sponsoring clinical trial NCT05397951?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397951 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05397951's enrollment target sits among peer trials
22 844th of 1090 higher than 235 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study
RECRUITING · NA
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Medical Illustration Design Characteristic Evaluation
RECRUITING · NA
-
Sodium vs Potassium Education to Improve Vascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI